• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
180311 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  5 L5 i0 K5 i6 _! Q
( G7 h5 U# _& @. o3 a% X+ n) e# j* S
3 a' t' P+ b0 y5 K1 p" q
Sub-category:
* n/ g8 g7 D) H' W0 I; UMolecular Targets . L0 F5 [% ]7 H7 v1 c2 B8 u6 E

' s3 e" I2 B6 ~
1 _/ d: c* q) k8 q* N( iCategory:7 H2 Q! W% m$ s3 R1 g
Tumor Biology
0 q6 I" `$ ^: B& ~* ^+ X
- U: y8 i( v  ^% O( T
- k# E; H. s& x8 U9 U4 TMeeting:
* A7 W9 A% ^  y1 t& T2011 ASCO Annual Meeting
( ?3 {4 X/ ?. g
2 n! |5 E3 E- V7 s6 c
9 d2 ~9 {1 O& h6 l( h3 |$ VSession Type and Session Title:
# J$ i5 v/ d5 Q5 s+ FPoster Discussion Session, Tumor Biology . E! P8 r1 o; a7 b8 O" Z# u# k

( w' `5 {% E- T$ T4 u  }$ E( C  P' X2 b* \- {, b+ |! V  c/ C
Abstract No:
4 ^0 F7 `7 c- G, w10517
1 Q( b5 }! h0 X# F
/ {1 J* D7 T1 T+ n8 W8 @; ]$ \" L, Q2 K; w
Citation:- u$ I; O1 L, s
J Clin Oncol 29: 2011 (suppl; abstr 10517) $ ~" o/ S5 S3 R5 k) I+ n" y/ S

& u6 a+ |* a6 r5 ?
6 H/ M8 p! t. h& v( \+ qAuthor(s):
4 S" P) j9 A! B) F/ q" X  h4 aJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China / w: R3 ^$ a  a' s  {% k" c9 q

: M2 t/ E! j; J- z9 ?( Y0 G# t3 U9 U0 i! `* H4 B( b" v

& ^* G7 |2 ?4 cAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.% {, Q: v. M! c
" B8 q3 V# a; ^
Abstract Disclosures0 q: i* q; d0 G% n+ b1 R8 y
, L, f. Z9 U4 R8 `
Abstract:! M4 b; S0 D& Y

6 ~" e' U* I* ^7 ~2 w: z
- e9 Y) t; X) aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.1 w: Q! c, n' Q! I' T  ^( @6 e
9 ^7 N' a1 P- _+ C# g& `
+ J  n( r5 m; S
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 . V' U9 X. |  n+ q3 D+ m
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
1 Y5 Q0 u# w7 Z: R' w9 I% X1 ~
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
: R& D, ~" W1 R. U易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
# O; @& {9 p/ tALK一个指标医院要900多 ...
, {% N4 M2 T. r8 w& ]: ?
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?1 K4 z8 l4 n  h% e5 \. [, s# k

; z+ M& B- x+ ?现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表